TAS2R14 and adrenal cortex carcinoma: Kaplan–Meier survival analyses for high- and low-expression groups of TAS2R14 were statistically significantly associated with survival for adrenocortical cancer (p = 0.0011), non-papillary bladder cancer (p = 0.0025), and esophageal adenocarcinoma (p = 0.026; Fig. 6A–E).